Renaissance Technologies LLC lifted its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 146.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 618,942 shares of the company's stock after purchasing an additional 368,071 shares during the period. Renaissance Technologies LLC owned about 0.23% of Autolus Therapeutics worth $1,455,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently bought and sold shares of the company. State Street Corp grew its holdings in Autolus Therapeutics by 1.7% in the third quarter. State Street Corp now owns 606,544 shares of the company's stock valued at $2,202,000 after purchasing an additional 10,401 shares during the period. JPMorgan Chase & Co. grew its stake in Autolus Therapeutics by 145.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company's stock valued at $4,663,000 after acquiring an additional 761,008 shares during the period. Hennion & Walsh Asset Management Inc. purchased a new stake in Autolus Therapeutics in the 4th quarter worth $611,000. Avanza Fonder AB acquired a new position in Autolus Therapeutics during the fourth quarter worth $75,000. Finally, Arkadios Wealth Advisors purchased a new position in Autolus Therapeutics during the fourth quarter valued at $47,000. Institutional investors and hedge funds own 72.83% of the company's stock.
Autolus Therapeutics Stock Performance
AUTL stock remained flat at $1.35 during mid-day trading on Friday. 3,017,804 shares of the company's stock were exchanged, compared to its average volume of 1,425,717. The company's fifty day moving average price is $1.58 and its 200 day moving average price is $2.36. Autolus Therapeutics plc has a 12 month low of $1.11 and a 12 month high of $5.00. The stock has a market cap of $359.23 million, a PE ratio of -1.12 and a beta of 1.77.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.12. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $2.98 million. On average, research analysts forecast that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.
Analysts Set New Price Targets
Several research firms recently weighed in on AUTL. Wells Fargo & Company reduced their price target on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research report on Friday, March 21st. Truist Financial reduced their target price on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Needham & Company LLC restated a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday, April 10th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Autolus Therapeutics presently has an average rating of "Buy" and an average price target of $9.32.
Read Our Latest Stock Analysis on Autolus Therapeutics
About Autolus Therapeutics
(
Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Featured Articles
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
